Skip to Content
Merck
All Photos(1)

Key Documents

937266

Sigma-Aldrich

NanoFabTx for gene delivery

Maleimide lipid mix

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352142
NACRES:
NA.21

Quality Level

application(s)

advanced drug delivery

storage temp.

−20°C

General description

Maleimide lipid mix for gene delivery and targeted delivery
The NanoFabTx gene delivery maleimide lipid mix is a ready-to-use nanoformulation lipid mixture for the synthesis of maleimide-functionalized lipid nanoparticles (LNPs).These lipid nanoparticles can be used for targeting and immunotherapy applications, and nucleic acid encapsulation.

This product is a curated lyophilized lipid mixture of rationally selected lipids in precise ratios that have been optimized to achieve a desired size range of lipid nanoparticles. Step-by-step protocols for the synthesis of maleimide-functionalized LNPs by microfluidics with the NanoFabTx microfluidic- nano device kit (Cat. No. 911593) or nanoprecipitiation are included.

Maleimide-functionalized LNPs are particularly advantageous for gene delivery because the maleimide functional group enables the conjugation of thiol-containing antibodies, proteins, aptamers, or other molecules to the lipid nanoparticle surface. This can be used for multi-targeting or multi-type cargo delivery to different cell types including immune cells, making it advantageous for many different therapuetic applications including mRNA vaccine delivery and oncology.

Application

With the NanoFabTx gene delivery maleimide lipid mix, researchers can simplify their drug development workflow. The ready to use mix enables the screening of different drug modalities such as oligonucleotides, nucleic acids (mRNA, DNA, siRNA), and vaccines without the need to develop new drug delivery formulations from scratch, ultimately speeding up the time it takes for innovative therapeutics to go from the bench to the clinic. The maleimide-functionalized surface of the LNP can be used to conjugate to many different thiol-containing biomolecules for active targeting. This ready-to-use lipid mix can also be used to screen different targeting moieties to determine what works best for your therapuetic and application. In addition, the lipid mix has been carefully crafted for enhanced gene delivery.

Features and Benefits

  • A ready-to-use nanoformulation lipid blend to synthesize Maleimide-functionalized lipid nanoparticles
  • Step-by-step protocols developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible lipid nanoparticles
  • Optimized to make lipid nanoparticles around 100 nm with low polydispersity
  • Optimized lipid blend for thiol-containing protein or antibody conjugation
  • Optimized lipid blend for Maleimide-functionalized lipid nanoparticles for mRNA encapsulation
For more information, please refer to the protocol under the document section of this page.

Legal Information

Legal Information NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Dammes N, et al.
Nature Nanotechnology, 16(9), 1030-1038 (2021)
In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
Fang-Yi S, et al.
Science advances, 8(8), eabm7950- eabm7950 (2022)
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
Tombacz I, et.al.
Molecular Therapy, 29(11), 3293-3304 (2021)
István Tombácz et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(11), 3293-3304 (2021-06-07)
Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular
Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai Y, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 349, 379-387 (2022)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service